My husband, Jason, and I are parents to seven children: Lexi, 23; Max, 19; Chance, 17; Rowen, 16; Charlie, 14; Mary, 10; and Callie, 3. This week we’re traveling ...

The successful launch of Elevidys, Sarepta’s gene therapy for DMD, has been a key driver of the company’s recent performance. Following the full-label expansion for Elevidys in DMD patients aged 6 ...

The price you pay for Elevidys may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

The Business Research Company Elevidys Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs”&mdash ...

Q4 2024 earnings showed 75% Y/Y revenue growth, driven by Elevidys, with net income tripling to $159.049 million and EPS of $1.50. Sarepta's pipeline includes gene therapies for LGMD, FSHD ...

When Jason Abaluck saw how a colleague was describing his research in court filings, he was annoyed. He’d just been over this. It had started on Sept. 1, 2021, when he’d noticed Stanford ...

and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Families affected by DMD saw a spate of treatment approvals in 2023 and 2024, including Sarepta Therapeutics’ Elevidys and Catalyst Pharmaceuticals’ Agamree. The most recent was Duvyzat (givinostat), ...

6. Elevidys for Duchenne muscular dystrophy (DMD) On June 20, 2024, the FDA expanded the approval of Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy initially ...

Management is confident in FY25 guidance given clear visibility, notes the analyst, who is “encouraged” by the strong commercial performance of the Elevidys launch to-date and what the firm ...

Sarepta Therapeutics, Inc. SRPT reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks Consensus Estimate of $1.87. However, the reported figure was significantly ...